TrialCancer immunology, immunotherapy : CII2004

Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.

Deanne M R Lathers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.